Active, Not Recruiting
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab - CA204-185
Updated: 15 April, 2024 | ClinicalTrials.gov
Phase
Gender(s)
Age Range
Active, Not Recruiting
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participated in a previous elotuzumab protocol (including, but not limited to HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol - Receiving elotuzumab and/or other study drugs at the time of signature of informed consent - Males and Females, ages 18 and older Exclusion Criteria: - All participants previously discontinued from an elotuzumab study for any reason - Participants not receiving clinical benefit from previous study therapy - Participants who are not medically well enough to receive study therapy as determined by the investigator Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
